 |
| Attached files |
| File | Filename |
|---|
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R7.htm |
| 10-Q - Q Therapeutics, Inc. | form10q.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R13.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R23.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R25.htm |
| EX-32.2 - Q Therapeutics, Inc. | ex32-2.htm |
| EX-32.1 - Q Therapeutics, Inc. | ex32-1.htm |
| EX-31.2 - Q Therapeutics, Inc. | ex31-2.htm |
| EX-31.1 - Q Therapeutics, Inc. | ex31-1.htm |
| EX-14.1 - Q Therapeutics, Inc. | ex14-1.htm |
| EX-3.2 - Q Therapeutics, Inc. | ex3-2.htm |
| EX-3.1 - Q Therapeutics, Inc. | ex3-1.htm |
v2.4.0.6
|
Private Placement Memorandum (Details Narrative) (USD $)
|
6 Months Ended |
9 Months Ended |
|
Jun. 30, 2012
|
Sep. 30, 2012
Minimum [Member]
|
Jun. 30, 2012
Minimum [Member]
|
Sep. 30, 2012
Maximum [Member]
|
Jun. 30, 2012
Maximum [Member]
|
Sep. 30, 2012
Range One [Member]
|
Sep. 30, 2012
Range Two [Member]
|
| Private placement number of units offered |
|
|
3,000,000 |
|
6,000,000 |
|
|
| Exercisable price of warrant |
|
$ 1.25 |
|
$ 2.75 |
|
$ 1.00 |
$ 2.00 |
| Units sold from Private placement of common stock |
4,018,047 |
|
|
|
|
|
|
| Net proceeds from Private Placement |
$ 3,820,318 |
|
|
|
|
|
|
| Issuance cost for private placements |
$ 197,729 |
|
|
|
|
|
|
| X |
- Definition
Private Placement Number of Units Offered
+ References+ Details
| Name: |
qhoi_PrivatePlacementNumberofUnitsOffered |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References+ Details
| Name: |
us-gaap_DebtIssuanceCosts |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585
+ Details
| Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section H
+ Details
| Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by Q Therapeutics, Inc. and has no official or unofficial affiliation with Q Therapeutics, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
